Background Vitiligo is a chronic disorder causing skin depigmentation with global prevalence varying from 0Á2% to 1Á8%. U.K. guidelines recommend assessment of psychological state during clinical evaluation of vitiligo. However, the prevalence of psychological comorbidity in people with vitiligo has not been described. Objectives To establish the prevalence of psychological symptoms or disorders in people with vitiligo and describe the outcome measures used. Methods We performed a comprehensive search of MEDLINE, Embase, CINAHL and PsycINFO to identify observational studies assessing the prevalence of psychological symptoms or disorders (December 2016). DerSimonian and Lard random-effects models were used to estimate the overall pooled prevalence. Results We identified 29 studies with 2530 people with vitiligo. Most studies included a measure of either depression (n = 25) or anxiety (n = 13). The commonest tools were the Hospital Anxiety and Depression Scale and the Centre for Epidemiology Studies Depression Scale. Ten studies provided information on 13 other psychological outcomes. Pooled prevalence using depression-specific and anxiety-specific questionnaires was 0Á29 [95% confidence interval (CI) 0Á21-0Á38] and 0Á33 (95% CI 0Á18-0Á49), respectively. Prevalence was lower for clinically diagnosed depression (0Á21, 95% CI 0Á15-0Á28) and anxiety (0Á15, 95% CI 0Á06-0Á24). When nonspecific tools were used the prevalence remained similar for depression (0Á27, 95% CI 0Á08-0Á46) but increased for anxiety (0Á46, 95% CI 0Á39-0Á52). High heterogeneity was observed. Conclusions A range of psychological outcomes are common in people with vitiligo. The prevalence of anxiety was influenced by type of screening tool, suggesting the need for validation of psychological outcome screening tools in the field of dermatology.
• Validation of psychological outcome screening tools in the field of dermatology should be considered.
Vitiligo is an acquired chronic disorder of skin pigmentation caused by the selective destruction of melanocytes. 1 It causes milky-white patches or macules on the skin, most commonly in exposed areas of the body such as the hands and face. 2 Vitiligo occurs equally in both sexes and all ethnicities, and may develop at any age, although it most commonly presents in children and young adults. 1 The global prevalence varies from 0Á2% to 1Á8%. 3 The aetiology of vitiligo is not fully understood. Autoimmune, genetic and environmental factors probably combine to give a mixed aetiology. [4] [5] [6] A recent Cochrane systematic review concluded that there is currently no cure for the condition although there are various treatments/interventions available to manage vitiligo such as topical corticosteroids, calcineurin inhibitors, phototherapy and camouflage. 7 Although vitiligo is typically asymptomatic it may substantially affect the psychological well-being of people living with the condition. [8] [9] [10] [11] [12] This may be as a result of the burden associated with the visibility of vitiligo and its consequent impact on interactions with others. 13 Another reason may be the unpredictable prognosis and the current lack of a cure. The British Association of Dermatologists recommends assessment of psychological state and quality of life during the clinical evaluation of people with vitiligo. 2 Furthermore, a recent systematic review has shown that people with vitiligo are significantly more likely to have depression and impaired general health than those without vitiligo. 14 However, there is a lack of knowledge of the other types of psychological symptoms or disorders that people with vitiligo experience. Such information may help the development of future trials of psychological interventions in people with vitiligo. A Cochrane review found only one randomized controlled trial on the effectiveness of psychological interventions in people with vitiligo. 7 Evaluating the effectiveness of psychological interventions for this patient group was one of the top-10 research priorities identified by the James Lind Alliance's vitiligo Priority Setting Partnership. 15 To date, no systematic review on the prevalence of psychological comorbidity in people with vitiligo has been conducted. Therefore, this review aimed to synthesize all available evidence from observational studies on the prevalence of psychological symptoms or disorders in people living with vitiligo.
Patients and methods
The study protocol was registered with the National Institute for Health Research International prospective register of systematic reviews (PROSPERO) on 21 March 2016 and is available at http://www.crd.york.ac.uk/prospero (registration number CRD42016036193). We initially planned to look at two primary outcomes: (i) psychological comorbidity and (ii) quality of life within the same study. However, because of the number of studies found and the theoretical difference between quality of life and psychological symptoms or disorders, it was decided it would be more appropriate to assess these outcomes separately. The systematic review on quality of life in people with vitiligo has been published. 16 The methods used for this review were reported in accordance with the PRISMA statement. 17 
Literature search
On 21 December 2016, a literature search in MEDLINE (Ovid), Embase (Ovid), PsycINFO and CINAHL was performed. Records from the inception of each database were accessed. The search strategy was developed by O.O. after consultation with an information specialist with experience in dermatology (D.G.). The strategy included the search terms 'vitiligo', 'leucoderma', 'leukoderma', 'psychology', 'depression', 'anxiety' and 'mental health' (Table S1 ; see Supporting Information). The use of these search terms appeared sufficient in capturing psychological comorbidity and it was consequently deemed as unnecessary to conduct searches using all known diagnostic categories. Grey literature was searched at this website: http://www.bl.uk/reshelp/findhelprestype/theses/ethos/in dex.html. Reference tracking of key papers and citation searching in Google Scholar were also conducted.
Eligibility criteria
We included observational studies (cohort, case-control, cross-sectional and case series) that reported data on the prevalence or incidence of any psychological outcome in people with vitiligo. Ecological studies, policy statements, editorials/reviews and randomized controlled clinical trials involving any form of intervention were excluded. Trials were excluded as people included in trials may not be representative of people from everyday clinical practice and to keep this work manageable within the time frame available. 18 There was no restriction on age, sex, type of vitiligo, ethnicity or publication language. Vitiligo had to have been diagnosed clinically by a clinician or dermatologist. The psychological outcomes of interest were any form of psychological symptom or disorder that was either self-reported or clinically diagnosed.
Selection
Two authors (O.O. and S.R.) independently assessed studies for eligibility using a two-stage sifting process. The titles and abstracts were reviewed simultaneously and subsequently the full-text copies of potentially relevant studies were screened. Results of the independent assessments by each author were compared and differences were resolved through discussion. A citation search using Google Scholar and reference lists of key papers were searched by hand for relevant studies to increase the sensitivity of our search.
Data extraction
Two authors (O.O. and L.H.) independently extracted information from the included studies using a piloted template and any disparity was resolved by discussion. The translation and data extraction of the Spanish, French and Italian papers were conducted by researchers proficient in these languages.
Evaluation of methodological quality of the included studies
The methodological quality of the included studies was evaluated by combining and adapting the Newcastle-Ottawa 19 and the National Heart Lung and Blood Institute scales. 20, 21 Modification of the Newcastle-Ottawa scale was required because of concerns about the vagueness of decision rules in relation to the focus of our review and the National Heart Lung and Blood Institute scale was used to include a tool for cross-sectional studies (Tables S2 and S3; see Supporting Information) . Quality assessment was conducted independently by three of the researchers (O.O., L.H. and S.R.). A score of ≥ 70% was rated as good, 50-69% as fair and < 50% as poor.
Data analysis
Pooled prevalence (expressed as a proportion) of depression and anxiety according to depression/anxiety-specific, nondepression/nonanxiety-specific questionnaires and psychiatric diagnosis was calculated. For controlled studies, studies were pooled to determine relative risk when there were a sufficient number of studies ≥ 3. Random-effects model of DerSimonian and Lard was used to account for variance between and within studies. 22 Heterogeneity between studies was assessed using the I 2 -statistic, with values of 25%, 50% and 75% considered to demonstrate low, moderate and high heterogeneity, respectively. 23 All analyses were performed using Stata version 14.0 (StataCorp, College Station, TX, U.S.A.). For psychological outcomes that were not included in the meta-analysis, a narrative synthesis was conducted. 
Results

Study selection
The execution of the search strategy initially resulted in 1000 studies after duplicates were removed. After screening titles and abstracts, 98 studies were obtained for full review. Of these, 24 fulfilled the inclusion criteria for the systematic review ( Fig. 1) . A search through the grey literature database identified no further studies. However, a citation search using Google Scholar identified two further eligible papers and reference tracking identified three eligible studies, giving a total of 29 included studies.
Description of included studies Table 1 summarizes the general characteristics of the 29 eligible studies (2530 vitiligo patients in total). Twenty-six of the studies were cross-sectional and three studies were casecontrol. Eleven studies included comparator groups; these consisted of participants diagnosed with other dermatological diseases such as acne, psoriasis, albinism, alopecia areata, skin cancer, neurodermatitis, eczema or healthy participants that were either related to or accompanying the participants to the clinics/hospitals or hospital staff. There were seven studies conducted in Europe, 13 studies from Asia, 3 studies from the Americas, 3 studies from the Middle East and the remaining 3 studies were from Africa. Sample size ranged from nine to 326 people. The participants were recruited from either hospitals (n = 24) or dermatology clinics (n = 4) or from both (n = 1).
Psychological outcomes
The most common psychological outcomes in the studies reviewed was depression (n = 25 studies) ( Table 2) . Anxiety was reported in 13 studies; two of these reported on generalized anxiety (Table 3) . Ten studies reported on 13 less commonly reported outcomes: substance misuse, suicidal attempts, panic disorder, social phobia, dysthymic disorder, adjustment disorder, alcohol addiction, asthenia, interpersonal conflict, insomnia, obsessive-compulsive disorder, specific phobia and agoraphobia. (Table 4 ). The focus of our analysis is on depression and anxiety as these are the two most common outcomes.
Outcome measurement tools
Nineteen different outcome tools were used in total including depression-specific or anxiety-specific questionnaires [e.g. four of these did so after screening with the GHQ (Table 1) . [28] [29] [30] 40 Quality of studies A score of ≥ 70% was rated as good, 50-69% as fair and < 50% as poor. Of the 29 studies, four (14%) were of poor quality, 13 (45%) were of fair quality and 12 (41%) were of good quality (Table 1) .
Prevalence of depression
A total of 25 studies including 2071 patients with vitiligo reported data on the prevalence of depression. Table 2 summarizes the general characteristics of each study. A total of 14 different outcome tools were used to assess depression including five depression-specific tools (n = 11 studies) and four nondepression-specific tools (n = 4 studies); clinical examination was conducted in nine studies using the ICD-10 or Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) or the tool was not stated. One study used a questionnaire but did not provide further details (and this has been classified as a nondepression-specific questionnaire). In two studies clinical examination was conducted only for patients within a certain GHQ threshold (this is why the total number of patients in Table 2 is greater than 2071).
28,30
The pooled prevalence of depression among patients with vitiligo based on depression-specific questionnaires was 0Á29 (95% CI 0Á21-0Á38), as shown in Figure 2 . There was substantial heterogeneity between the studies (I 2 = 89%, P < 0Á001). Using nondepression-specific questionnaires, the pooled prevalence was similar 0Á27 (95% CI 0Á08-0Á46) with higher heterogeneity (I 2 = 97Á5%, P < 0Á001); using clinical diagnosis, the pooled prevalence was lower 0Á21 (95% CI 0Á15-0Á28) with lower heterogeneity (I 2 = 61Á81%, Eleven studies presented the prevalence of depression in a comparator group. The most common comparator was people with psoriasis with five studies including 172 patients with vitiligo. Only the study conducted by Mattoo et al., 28 matched the control and the vitiligo participants (by sex and education). The overall risk of depression was less in people with vitiligo compared with those with psoriasis; pooled relative risk was 0Á66 (95% CI 0Á48-0Á90); there was no heterogeneity (Fig. 3) . The second most common comparator was healthy controls (n = 4 studies; but only two of these reported the prevalence of depression in the comparator groups). 42, 51 In both studies, the prevalence of depression was higher in patients with vitiligo compared with the healthy controls. The healthy controls and participants with vitiligo were similar in terms of age and sex in the study conducted by Balaban et al. 42 but not in the study by Karia et al.
51
Prevalence of anxiety
Thirteen studies including 866 patients with vitiligo patients reported data on the prevalence of anxiety. Table 3 summarizes the general characteristics of each study. A total of five different outcome tools were used to assess this disorder including three anxiety-specific tools (n = 5 studies) and two nonanxiety tools (n = 2 studies); and clinical examination by a psychiatrist was conducted in six studies. The pooled prevalence of anxiety among patients with vitiligo based on anxiety-specific questionnaires was 0Á33 (95% CI 0Á18-0Á49), as shown in Figure 4 . There was substantial heterogeneity between the studies (I 2 = 89Á2%, P < 0Á001).
Using nonanxiety-specific questionnaires, the pooled prevalence was higher at 0Á46 (95% CI 0Á39-0Á52) with higher heterogeneity (I 2 = 96Á2%, P < 0Á001). Using clinical diagnosis, the prevalence was substantially lower at 0Á15 (95% CI 0Á06-0Á24) but heterogeneity was still very high (I 2 = 88Á7%, P < 0Á001).
Nine studies presented the prevalence of anxiety in a comparator group . The most common comparator was psoriasis with four studies including 119 patients with vitiligo. Only the study conducted by Mattoo et al. 28 matched the control group and the participants with vitiligo by sex. The pooled relative risk of anxiety in people with vitiligo compared with those with psoriasis was 0Á80 (95% CI 0Á57-1Á13) and there was no heterogeneity ( Figure 5 ). The second most common comparator was healthy controls. 42, 51 The prevalence of anxiety was higher in individuals with vitiligo compared with healthy controls. The control group was matched on age and sex in the study conducted by Balaban et al.
42
Prevalence of other psychological outcomes
Ten studies including 577 patients with vitiligo provided data on 13 less commonly reported psychological outcomes. Table 4 summarizes the general characteristics of each study. The majority of these studies were based in Asia (n = 6 studies). The most commonly reported psychological outcome was social phobia (n = 4 studies); the prevalence varied from 2Á4% to 67Á9%; two studies used psychiatric clinical examination and two used self-reported questionnaires. Seven studies presented the prevalence of other psychological outcomes in a comparator group. The most common comparator was people with psoriasis (n = 4 studies). Apart from dysthymic disorder, the prevalence of the psychological outcomes was the same or lower, in those with vitiligo compared with those with psoriasis. Only two studies matched the vitiligo and comparator groups. Mattoo et al. 28 matched them in terms of sex and education whereas Balaban et al. 42 matched on age and sex.
Discussion
To our knowledge, this is the first systematic review that synthesizes the prevalence of different psychological outcomes in people with vitiligo. We demonstrated that people with vitiligo experience a range of outcomes on the spectrum of psychological symptoms or disorders including anxiety, substance misuse and suicidal attempts. The two most commonly reported outcomes were depression and anxiety, which were assessed using either self-reported questionnaires or clinical diagnosis made by a psychiatrist. Mattoo (2002) Sharma (2001) Mattoo (2001) Karia (2015) Ahmed ( Historically, vitiligo has been classed as a cosmetic problem; this is clearly not the case. 53 Qualitative studies indicate that vitiligo can have a huge psychological burden on people. 54 According to our review, approximately a quarter of patients with vitiligo reported depression symptoms using depressionspecific or general/mental health questionnaires and almost a fifth of them had clinical depression. However, they were significantly less likely to show symptoms of depression than people with psoriasis. The pooled prevalence of anxiety did differ depending on whether the diagnosis was made using anxiety-specific or general/mental health questionnaires ranging from 33% to 46%. However, it was substantially lower when diagnosed clinically (15%). Similar to depression, the risk of anxiety was lower in those with vitiligo than those with psoriasis, but this result was not statistically significant. The major strength of this review is the broad overview of the different psychological outcomes experienced by people with vitiligo. Searching four databases, including PsycINFO, helped ensure our search was comprehensive and improves on similar previous published work. 14 Including non-English papers, as far as possible, has reduced the potential for bias. We have also been able to conduct a meta-analysis to quantify the difference in depression and anxiety between people with vitiligo and those with psoriasis. Such information has not been reported previously.
The main limitation of this review is the high heterogeneity between the included studies. This may be because of the broad inclusion criteria. We have attempted to address study heterogeneity by employing a random-effects model. However, as a result of substantial heterogeneity, the results may not be generalizable to all patients with vitiligo. Information on the type and severity of vitiligo, which can be potential sources of heterogeneity, was not available in most studies. Also, the majority of the included studies did not have adequate controls, making the results susceptible to the effect of confounding factors. All studies were hospital or clinic based, which could also result in selection bias. As a result of the small number of studies, we were not able to conduct separate meta-analyses for different measurement tools when comparing the prevalence of depression and anxiety with those seen in people with psoriasis. We were also limited to comparing vitiligo with psoriasis and not other skin conditions or healthy controls. Finally, we had insufficient studies to assess publication bias.
The most relevant study to compare our findings with is that of Lai et al.
14 The authors conducted a systematic review to investigate the prevalence of depression and general health in people with vitiligo worldwide. Among studies reporting the prevalence of depression based on ICD codes, the pooled prevalence of depression among patients with vitiligo was 0Á253 (95% CI 0Á161-0Á345). Using DSM-IV criteria, the pooled prevalence decreased to 0Á122 (95% CI 0Á046-0Á197) and using self-reported questionnaires the prevalence of depressive symptoms was 0Á336 (95% CI 0Á248-0Á424). Their results, like ours, showed that use of questionnaires provided higher estimates of prevalence than clinical diagnosis. This is because questionnaires such as the Hospital Anxiety and Depression Scale and CES-D are often used to measure the presence of depressive symptomatology rather than the presence of the full criteria for a diagnosis of clinical depression to be made. The same rationale is applicable in the explanation as to why the prevalence of clinically diagnosed anxiety that we found was substantially lower than that reported by questionnaires. Lai et al. combined broad mental health and depression-specific self-reported questionnaires, which may explain why their pooled estimate of the risk of depression was higher than ours (0Á34 vs. 0Á29). We only combined questionnaires specific to measuring depression, as we believe this provides a more accurate estimate. We did not report prevalence separately for ICD and DSM-IV tools, as Lai et al. did, but reported prevalence for clinical diagnosis overall as it was unclear in some papers which tool was used. 26, 34 Finally, similar to Lai et al. we report that those with vitiligo are at higher risk of depression than healthy controls (without adjustment for confounders). Lai et al. did not compare the prevalence of depression in people with vitiligo with those with other skin conditions. This review has established that there are currently no large or population-based studies exploring the psychological impact of vitiligo. With the current availability of linked large routinely collected healthcare datasets [such as the Clinical Practice Research Datalink (https://www.cprd.com/home/) and Hospital Episode Statistics and Mental Health datasets] there is an opportunity for researchers to conduct large cost-effective studies at a population level with comparable controls that will provide more generalizable and less biased results in this field.
This review has shown the range of psychological screening tools, not all of which were validated, being used. Lack of sensitivity of the measurement tools and variability in the tool use may greatly increase the risk of producing inaccurate estimates of the prevalence of anxiety. It has been argued that the nine-item Patient Health Questionnaire and the seven-item Generalized Anxiety Disorder Assessment are useful pragmatic measures as they are free and widely used in primary care to assess depression and anxiety among people with skin conditions. 54, 55 Nevertheless, our findings indicate that there is a case for developing dermatology-specific validated scales. As approximately one in four people with vitiligo appear to have depression and at least one in seven have anxiety, assessment of psychological state during clinical evaluation of patients with vitiligo, as suggested by the British Association of Dermatology guidelines, 2 is essential. The same can be said for clinical evaluation of people with other skin conditions. In conclusion, people living with vitiligo experience a range of psychological symptoms or disorders. The prevalence of depression did not vary substantially by screening tool whereas the prevalence of anxiety did, suggesting the need for dermatological-specific validated screening tools in this group of patients. Population-based studies in this field are also required to provide more generalizable results.
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